Lanean...
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
PURPOSE OF REVIEW: The first monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) have been approved for clinical use. This timely review highlights recent developments. RECENT FINDINGS: Low-density lipoprotein cholesterol (LDL-C) is the primary driver of atheroscler...
Gorde:
| Argitaratua izan da: | Curr Opin Lipidol |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Lippincott Williams & Wilkins
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4927326/ https://ncbi.nlm.nih.gov/pubmed/26780005 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOL.0000000000000239 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|